– FDA grants traditional approval to ELEVIDYS for ambulatory Duchenne patients
– FDA grants accelerated approval to ELEVIDYS for non-ambulatory Duchenne patients
– Sarepta will host an investor conference call on June 21, 2024, at 8:30 a.m. ET
At 8:30 a.m. ET on June 21, 2024, Sarepta will host a conference call and webcast to discuss this update.
The event will be webcast live under the investor relations section of Sarepta’s website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.